lipid-conjugated siRNA therapeutic (University of Pennsylvania/DTx Pharma)

N/A

Report date: 2025/01/26 18:01:23
NME

Base Information

Drug Namelipid-conjugated siRNA therapeutic (University of Pennsylvania/DTx Pharma)
Drug Alias Namelipid-conjugated siRNA hTau gene therapy (University of Pennsylvania/DTx Pharma)
ClassificationSmall molecules > LipidSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNASmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionMicrotubule-associated protein tau inhibitors
TargetsMicrotubule-associated protein tau
Therapy Area/IndicationsFrontotemporal DementiaAlzheimer DiseaseSupranuclear Palsy, Progressive +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity Of Pennsylvania
China Registration ClassN/A

Develop Information

Active CompaniesNovartis AgUniversity Of Pennsylvania
Inactive CompaniesDTx Pharma Inc
Active IndicationsFrontotemporal DementiaAlzheimer DiseaseSupranuclear Palsy, Progressive +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A